首页|重构本草——益智仁

重构本草——益智仁

扫码查看
通过古籍文献调研、中药现代研究进展及其研究成果的梳理,结合中医临床及中药学等学科领域专家学者的认识及应用经验,经讨论认为益智仁:功效主要为暖肾固精缩尿、温脾开胃摄唾.症靶为多尿、流涎.现代药理研究认为,益智仁及其有效成分具有抑菌、调节排尿、保护肾脏、抗肿瘤、镇痛、镇静催眠、保护心血管、抗溃疡、调节胃肠、抗过敏、抗氧化、抗衰老、改善记忆力、保护神经等作用.本品无毒,但阴虚火旺或因热而患遗滑崩带者忌服.临床常用剂量为5~30 g,内服时根据不同疾病,或同一疾病的不同阶段进行辨证使用,并积极探索益智仁与症靶的量效关系构建.
Reconstruction of Chinese Materia Medica-sharp-leaf glangal fruit
Through investigation of ancient books and the sorting of the research progress and modern research achievements of traditional Chinese medicine,combined with the understanding and application experience of experts and scholars in desciplinary fields such as traditional Chinese medicine clinical medicine and science of Chinese materia medica,it is concluded that sharp-leaf glangal fruit mainly has the effects of warming the kidneys,controlling nocturnal emission by literal meaning and reducing urination,warming spleen,appetizing flavor and absorbing saliva.The symptom targets are polyuria and salivation.Modern pharmacological studies have found that sharp-leaf glangal fruit and its active ingredients have antibacterial,urinary regulation,kidney protection,anti-tumor,analgesic,sedative hypnotic,cardiovascular protection,anti ulcer,gastrointestinal regulation,anti allergy,antioxidant,anti-aging,memory improvement,and nerve protection effects.This product is non-toxic,but it should be avoided for those with hyperactivity of fire due to yin deficiency,or those who suffer from nocturnal emission and metrorrhagia and metrostaxis.The clinical dosage is 5-30g.When taken orally,it should be used based on syndrome differentiation according to different diseases or different stages of the same disease,and the construction of dose-effect relationship between the dosage of sharp-leaf glangal fruit and the symptom target should be explored actively.

sharp-leaf glangal fruitsymptom targetreconstruction of Chinese materia medicaclinical verification

康梦娇、汤梓晗、赵林华、张伟

展开 >

浙江中医药大学第一临床医学院,杭州 310053

河北医科大学中西医结合学院,石家庄 050031

中国中医科学院广安门医院代谢病研究所,北京 100053

甘肃中医药大学基础医学院,兰州 730000

展开 >

益智仁 症靶 重构本草 临床回归

2024

长春中医药大学学报
长春中医药大学

长春中医药大学学报

CSTPCD
影响因子:0.916
ISSN:1007-4813
年,卷(期):2024.40(12)